The tangled history of mRNA vaccines.

  title={The tangled history of mRNA vaccines.},
  author={Elie S. Dolgin},
  volume={597 7876},
  • E. Dolgin
  • Published 1 September 2021
  • History
  • Nature
Comparison of Physicochemical Properties of LipoParticles as mRNA Carrier Prepared by Automated Microfluidic System and Bulk Method
Polymeric and/or lipid platforms are promising tools for nucleic acid delivery into cells. We previously reported a lipid–polymer nanocarrier, named LipoParticles, consisting of polylactic acid
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Several interventions to encourage vaccination have been studied, including education programs and non-monetary incentives with the most effective studies using a combination of methods.
Making COVID-19 mRNA vaccines accessible: challenges resolved.
INTRODUCTION The SARS-CoV-2 virus arrived in late 2019, infected half a billion across the globe, and killed more than 6.5 million; had it not been for the fast entry of vaccines, billions may have
The Past, Present, and Future of Non-Viral CAR T Cells
How the use of non-viral vectors can address some of the limitations of the viral methods of gene transfer and allow us to deliver genetic information in a stable, effective and straightforward manner is discussed.
Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines
A general overview of the use of PEGylated nanoparticles for pharmaceutical applications is provided, and the activation of the complement cascade that might be caused by P EGylated nanomedicines is discussed for a better understanding of these immunological adverse reactions.
The Kairos of COVID-19 Pandemic and the Quest for a New Life: A Paul Tillich Interpretation of History
This article brings alive Paul Tillich’s theological interpretation of history during COVID-19 as kairos. Kairos is explored in relation to three themes: creativity in science and its consequence of
Perspective Technologies of Vaccination: Do We Still Need Old Vaccines?
Until December 2019, we were living in the world of successfully functioning vaccines and vaccination programs [...]
Covid-19, an unfinished story
What to Expect from COVID-19 and from COVID-19 Vaccine for Expecting or Lactating Women
Evidence from both animals and humans suggest that, similarly to other vaccines routinely administered in pregnancy, COVID-19 vaccines are not crossing the placenta, do not increase the risk of miscarriage, preterm birth, stillbirth, the birth of small gestational age neonates, as well as the riskof congenital abnormalities.
A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2
While these pandemics are caused by distinct viruses, that ignited in different time periods and in different regions of the globe, the work shows that many of the determinants of their emergence and countermeasures used to halt transmission were common.


Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
2 CVnCoV doses were safe, with acceptable reactogenicity and 12 μg dosages elicited levels of immune responses that overlapped those observed in convalescent sera from known COVID-19 patients, an interim analysis of a dosage escalation phase 1 study in healthy 18–60-year-old volunteers.
In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies
Both naked and protected RNA can be used to elicit a specific immune response in vivo, whereby the protected RNA is stable in vitro for a longer period of time.
Cationic liposome-mediated RNA transfection.
We have developed an efficient and reproducible method for RNA transfection, using a synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), incorporated into
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
The induction of anti‐influenza cytotoxic T lymphocytes (CTL) in vivo by immunizing mice with liposomes containing messenger RNA (mRNA) encoding the influenza virus nucleoprotein (NP) is described and the relevance of these results in the context of vaccine development is discussed.
Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs.
The method of mRNA synthesis involves in vitro transcription of cDNAs which have been cloned into SP6 vectors and enables one to produce large amounts of mRNA and consequently protein from any cDNA clone.
Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA.
In Brattleboro rats, injection into the hypothalamus of purified mRNAs from normal rat hypothalami or of synthetic copies of the vasopressin mRNA leads to selective uptake, retrograde transport, and expression of vasoppressin exclusively in the magnocellular neurons.
mRNA Is an Endogenous Ligand for Toll-like Receptor 3*
Evidence is presented that heterologous RNA released from or associated with necrotic cells or generated by in vitro transcription also stimulates TLR3 and induces immune activation and this finding has potential physiologic relevance because RNA escaping from damaged tissue or contained within endocytosed cells could serve as an endogenous ligand forTLR3 that induces or otherwise modulates immune responses.